Compare Becton Dickinson and Co (BDX) vs Bumble Inc (BMBL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Bumble Inc — how do they compare? Becton Dickinson and Co trades at $156.38 (market cap $41.51B), while Bumble Inc trades at $2.99 (market cap $382.16M). The key difference: Becton Dickinson and Co is far larger — about 108.6× Bumble Inc's market cap, and Becton Dickinson and Co pays a 2.79% dividend while Bumble Inc pays none. Which is the better fit depends on your goals.
| BDX | BMBL | |
|---|---|---|
Market Cap | $41.51B | $382.16M |
Sector | Health | Technology |
52-Week High | $185.39 | $8.57 |
52-Week Low | $135.49 | $2.70 |
Enterprise Value | $57.97B | $733.84M |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
BMBL trades at $3.11, up 2.64% over 24 hours, with a neutral technical signal and bearish moving averages. The company reported a Q1 2026 EPS beat but faces declining revenue and a net loss of -$693.14M for 2025. Recent news highlights a potential sale exploration and an AI-driven product overhaul to counter slowing growth and payer declines.
Outlook remains speculative with a consensus price target of $4.37, offering 40% upside, but risks include persistent losses, high debt, and intense competition. Execution of the strategic reset is critical for a turnaround, with cash flow improvements providing a slight cushion amid operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Bumble Inc
Bumble Inc is engaged in offering online dating services. The company operates two apps, Bumble and Badoo, where users come on a monthly basis to discover new people and connect with each other.
Read more on BMBL →
